Why Can’t Hyper-Partisans Admit TrumpRx Is Dramatically Slashing Drug Costs?

In this RedState article, Carole Dykhouse argues that critics are ignoring major drug-price reductions tied to TrumpRx because they would rather defend government-heavy healthcare narratives than acknowledge results from President Trump’s negotiation-based approach.

• Dykhouse pushes back against a Daily Kos critique claiming TrumpRx.gov is not lowering drug prices as Trump has stated.
• The article cites several examples of lower prices listed through TrumpRx, including Pristiq dropping from $435 to $200 and Ngenla dropping from $4,434 to $2,217.
• Other examples include Xeljanz falling from $2,277 to $1,518 and Orencia SC dropping from $6,070 to $3,660.
• Dykhouse argues that even frequent Trump critic Mark Cuban has endorsed the effort, suggesting the price reductions are difficult to dismiss on partisan grounds.
• The piece frames TrumpRx as a market-oriented alternative to expanding bureaucracy, saying it achieved savings through private-sector cooperation rather than new government programs.
• The article says Trump negotiated with major pharmaceutical companies, including Pfizer, Eli Lilly, and Novo Nordisk, while also using tariff threats and domestic manufacturing incentives as leverage.
• Pfizer is cited as describing its arrangement as a “voluntary agreement with the U.S. government.”
• Dykhouse argues the broader lesson is that aggressive negotiation from the presidency can produce consumer benefits without relying on what she portrays as socialist mandates.
• The article says Trump announced an expansion of the website this month to include more than 600 generic drugs.

Read the full story: https://redstate.com/redstate-guest-editorial/2026/05/30/why-cant-hyper-partisans-admit-trumprx-is-dramatically-slashing-drug-costs-n2202849